胆脂瘤中纤溶酶原激活物质测定  

Detection of plasminogen activator in cholesteatoma

作　　者：温文胜[1] 黄光武[1] 余奇松[1] 小杉忠诚[2] 

机构地区：[1]南宁广西医科大学第一附属医院耳鼻咽喉科,530021 [2]日本琉球大学医学部

出　　处：《耳鼻咽喉（头颈外科）》2001年第4期241-244,共4页Chinese Arch Otolaryngology-Head Neck Surg

摘　　要：研究目的 :探讨纤溶酶原激活物 (plasminogen activator,PA)与胆脂瘤的关系 ,寻找治疗胆脂瘤型中耳炎的新方法。方法 :用纤维蛋白板测定 2 0例胆脂瘤组织和 8例正常外耳道上皮提取液的纤溶酶原激活物 ,同时进一步运用SDS-聚丙烯酰胺凝胶电泳和纤维蛋白自显影方法测定胆脂瘤组织提取液中 PA分子量。结果 :胆脂瘤组织提取液中的PA活性显著高于对照正常外耳道上皮 (P <0 .0 1)。胆脂瘤提取液中的 PA分子量为 2 3k D。结论 :本研究显示 PA在胆脂瘤慢性迁延过程中参与骨破坏作用 ,提示在胆脂瘤型中耳炎的治疗中 ,除常规抗炎和手术治疗外 ,抗纤溶药物或 PA抑制剂的运用或许会有一定意义。Objective:To determine the relationship between cholesteatoma and plasminogen activator(PA).Methods:The activity of PA were determined with fibrin plate in specimens of 20 cholesteatoma and 8 normal external ear canal skins.The molecular weight of PA was tested by SDS polyacrylamide slab gel electrophoresis and fibrin autography.Results:The activity of PA was higher in cholesteatoma than that in normal external ear canal skin(P<0 01).The molecular weight of PA was 23kD in cholesteatoma tissue .Conclusions:This study indicated that PA should play an important role in the chronic process of cholesteatoma.Result suggested that the antiplasmic agent or PA inhibitor in the therapy for cholesteatoma should be considered in clinical application in the future.

关 键 词：胆脂瘤 血纤维蛋白溶酶原激活剂 聚丙酰凝胶电泳 

分 类 号：R764.21[医药卫生—耳鼻咽喉科]